logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Showing 1 - 15 of 15 Items
Showing 1 - 15 of 15 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Using an analogue-digital hybrid clinical data management platform during a two-dose preventive Ebola virus vaccine trial in Goma, the Democratic Republic of the Congo

Brindle HE, Tetsa-Tata D, Edwards T, Choi EML, Kasonia K,  et al.
2025-05-02 • PLOS Global Public Health
2025-05-02 • PLOS Global Public Health

Clinical trials in settings with intermittent or non-existent internet and power connectivity, for example ...

Journal Article
|
Research

Pregnancy and neonatal outcomes in Eastern Democratic Republic of the Congo: a systematic review

Kasonia K, Brindle H, Manno D, Edwards T, Gardais S,  et al.
2024-12-05 • Frontiers in Global Women's Health
2024-12-05 • Frontiers in Global Women's Health

BACKGROUND

Conflict is known to impact maternal and neonatal health in Eastern Democratic Republic of the Congo (DRC), an area of longstanding insecurity. We co...

Journal Article
|
Research

Immunogenicity of an extended dose interval for the Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen in adults and children in the Democratic Republic of the Congo

Choi EM, Kasonia K, Kavunga-Membo H, Mukadi-Bamuleka D, Soumah A,  et al.
2024-07-26 • Vaccines
2024-07-26 • Vaccines

During the 2018–2020 Ebola virus disease outbreak in Democratic Republic of the Congo, a phase 3 trial of the Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine (DRC-EB-001) commenced in Goma, wit...

Journal Article
|
Research

Delivery and safety of a two-dose preventive Ebola virus disease vaccine in pregnant and non-pregnant participants during an outbreak in the Democratic Republic of the Congo

Kavunga-Membo H, Watson-Jones D, Kasonia K, Edwards T, Camacho A,  et al.
2024-07-23 • Vaccines
2024-07-23 • Vaccines

During the 2018–2020 Ebola virus disease (EVD) outbreak, residents in Goma, Democratic Republic of the Congo, were offered a two-dose prophylactic EVD vaccine. This was the first stud...

Journal Article
|
Commentary

The use of Ebola convalescent plasma to treat Ebola Virus Disease in resource constrained settings: a perspective from the field

van Griensven J, De Weiggheleire A, Delamou A, Smith PJ, Edwards T,  et al.
2015-08-10 • Clinical Infectious Diseases
2015-08-10 • Clinical Infectious Diseases
The clinical evaluation of convalescent plasma (CP) for the treatment of Ebola Virus Disease (EVD) in the current outbreak, predominantly affecting Guinea, Sierra Leone and Liberia, was ...
Conference Material
|
Abstract

Evolution of nutritional status in children aged 6-59 months with moderate acute malnutrition in India: a prospective longitudinal cohort study

Mahajan R, Edwards T, Shandilya C, Kashyap V, Marino E,  et al.
2021-05-19 • MSF Scientific Days International 2021: Research
2021-05-19 • MSF Scientific Days International 2021: Research
INTRODUCTION
Limited data exist to inform community management of children with moderate acute malnutrition (MAM), who are normally excluded from severe acute malnutrition (SAM) trea...
Journal Article
|
Research

Evaluation of convalescent plasma for Ebola Virus Disease in Guinea

van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P,  et al.
2016-01-07 • New England Journal of Medicine
2016-01-07 • New England Journal of Medicine
BACKGROUND
In the wake of the recent outbreak of Ebola virus disease (EVD) in several African countries, the World Health Organization prioritized the evaluation of treatment with co...
Journal Article
|
Research

Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial

Wassuna M, Njenga SN, Balasegaram M, Alexander N, Omollo R,  et al.
2016-09-14 • PLOS Neglected Tropical Diseases
2016-09-14 • PLOS Neglected Tropical Diseases
SSG&PM over 17 days is recommended as first line treatment for visceral leishmaniasis in eastern Africa, but is painful and requires hospitalization. Combination regimens including AmBis...
Conference Material
|
Abstract

Optimal mid-upper arm circumference-based discharge criteria for community-based-management of severe acute malnutrition in India: a randomized controlled non-inferiority trial

Burza S, Mahajan R, Edwards T, Shandilya C, Pereira AL,  et al.
2021-05-19 • MSF Scientific Days International 2021: Research
2021-05-19 • MSF Scientific Days International 2021: Research
INTRODUCTION
Most interventions for community-based management of severe acute malnutrition (CM-SAM) worldwide utilise mid-upper arm circumference (MUAC) <115mm for eligibility and ≥...
Protocol
|
Research Protocol

A randomized trial of AmBisome monotherapy and combination of AmBisome and miltefosine for the treatment of VL in HIV positive patients in Ethiopia followed by secondary VL prophylactic treatment with pentamidine

Hailu ADE, Diro EGJ, Kolja S, Ritmeijer KKD, Yifru S,  et al.
2018-07-01
2018-07-01
General Objectives
The overall objective of this trial is to identify a safe and effective treatment for VL in HIV coinfected
patients.
Primary Objective:
To evaluate...
Journal Article
|
Research

A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia

Diro EGJ, Blesson S, Edwards T, Koert R, Ritmeijer KKD,  et al.
2019-01-17 • PLOS Neglected Tropical Diseases
2019-01-17 • PLOS Neglected Tropical Diseases
BACKGROUND
Visceral leishmaniasis (VL) in human immunodeficiency virus (HIV) co-infected patients requires special case management. AmBisome monotherapy at 40 mg/kg is recommended by...
Journal Article
|
Research

Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia

Diro EGJ, Edwards T, Ritmeijer KKD, Fikre H, Abongomera C,  et al.
2019-02-21 • PLOS Neglected Tropical Diseases
2019-02-21 • PLOS Neglected Tropical Diseases
BACKGROUND:
The long-term treatment outcome of visceral leishmaniasis (VL) patients with HIV co-infection is complicated by a high rate of relapse, especially when the CD4 count is ...
Journal Article
|
Research

Geographical Variation in the Response of Visceral Leishmaniasis to Paromomycin in East Africa: A Multicentre, Open-Label, Randomized Trial

Hailu ADE, Musa AM, Wasunna M, Balasegaram M, Yifru S,  et al.
2010-10-26 • PLOS Neglected Tropical Diseases
2010-10-26 • PLOS Neglected Tropical Diseases
Visceral leishmaniasis (VL) is a major health problem in developing countries. The untreated disease is fatal, available treatment is expensive and often toxic, and drug resistance is in...
Conference Material
|
Slide Presentation

Longitudinal follow-up of children aged 6-59 months with Moderate Acute Malnutrition (MAM) in India: a prospective observational study​

Mahajan R, Edwards T, Shandilya C, Kashyap V, Marino E,  et al.
2021-05-19 • MSF Scientific Days International 2021: Research
2021-05-19 • MSF Scientific Days International 2021: Research
Protocol
|
Research Protocol

Protocol for a phase 3 trial to evaluate the effectiveness and safety of a heterologous, two-dose vaccine for Ebola virus disease in the Democratic Republic of the Congo

Watson-Jones D, Kavunga-Membo H, Grais RF, Ahuka S, Roberts N,  et al.
2022-03-08 • BMJ Open
2022-03-08 • BMJ Open
INTRODUCTION
Ebola virus disease (EVD) continues to be a significant public health problem in sub-Saharan Africa, especially in the Democratic Republic of the Congo (DRC). Large-scal...